Loading data for SCNX — first visit, this takes a few seconds.

Alert

Scienture Inc. (SCNX)

NasdaqCM: SCNX · Real-Time Price · USD

0.46

-0.01 (-2.13%)

At close: Aug 18, 2026, 8:00 PM

0.45

-2.60%

Pre-market: 4:36 AM

-2.13% (1D)

No data available

Bid	n/a
Market Cap	18.76M
Revenue (ttm)	821.32K
Net Income (ttm)	-37.95M
Beta	n/a
EPS (ttm)	-1.98
PE Ratio (ttm)	n/a
Forward PE	n/a
P/B (ttm)	0.28
P/S (ttm)	22.84
Earnings Date	n/a

Ask	n/a
Volume	525,504
Avg. Volume (20D)	2,538,061
Open	0.46
Previous Close	0.47
Day's Range	0.44 - 0.48
52-Week Range	0.24 - 2.60
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	Jul 19, 2024

About SCNX

Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left vent...

[Read more]

Industry Pharmaceutical Retailers

Sector Healthcare

IPO Date Feb 6, 2014

Employees 4

Stock Exchange NasdaqCM

Ticker Symbol SCNX

Website https://scienture.com

Full Company Profile

Financial Performance

In 2025, Scienture's revenue was 431.61K, an increase of 215.87% compared to the previous year's 136.64K. Earnings were -41.51M, a decrease of -557.9%.

Financial Statements

Earnings Surprise

Scienture has released their quarterly earnings on Aug 13, 2026:

Revenue of $56.33K misses estimates by $0, with 449.08% YoY growth.

EPS of -0.07 exceeds estimates by 0.02, with -Infinity% YoY decline.

News

6 days ago · InvestorsHub

SCIENTURE Launches REZENOPY as Second FDA-Approved Commercial Product

SCIENTURE has commercially launched REZENOPY, its 10 mg naloxone nasal spray, and fulfilled initial purchase orders to U. S.

6 days ago · Benzinga

EXCLUSIVE: Scienture Launches Highest-Dose Naloxone Nasal Spray Rezenopy in US

Pharmaceutical firm Scienture Holdings, Inc. (NASDAQ:SCNX) on Wednesday officially initiated the commercial rollout of Rezenopy, a 10-milligram naloxone hydrochloride nasal spray. The company has succ...

2 months ago · Benzinga

EXCLUSIVE: Scienture Expands Coverage For Opioid Overdose Treatment Ahead Of Commercial Launch

Scienture Holdings Inc. (NASDAQ:SCNX) said Tuesday that its opioid overdose treatment Rezenopy (naloxone HCl) Nasal Spray 10 mg has been added to the formulary of a large national health plan, broaden...

5 months ago · Associated Press Finance

BC-Most Active Stocks

Elong Power Holding Ltd. 79,546,080 0.0559

8 months ago · TipRanks

Scienture, BlinkRx announce strategic collaboration to expand access to Arbli

Scienture (SCNX) announced a strategic collaboration to expand national access to Arbli, the first FDA-approved, ready-to-use oral suspension formulation of losartan potassium. Arbli is expected to be...

Page 1 of 2

Scienture Inc. (SCNX)